Trials / Completed
CompletedNCT04076943
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Kyntra Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and effective for the treatment of anemia in participants receiving chemotherapy treatment for cancer.
Detailed description
This study consists of three periods: 1. Screening Period up to 28 days 2. Treatment Period of up to16 weeks 3. A Follow-up period of 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roxadustat | Roxadustat will be administered per schedule specified in the arm description. |
Timeline
- Start date
- 2019-08-20
- Primary completion
- 2021-03-26
- Completion
- 2021-04-23
- First posted
- 2019-09-04
- Last updated
- 2022-06-03
- Results posted
- 2022-06-03
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04076943. Inclusion in this directory is not an endorsement.